Our Partners
Business unusual is the founding DNA of Critica. We put humanity as the central way of thinking and working in business and as a way of living in society. We invite all those who share or wish to partake in this mentality to join us. We lead with our hearts, our minds and our smile.
Navamedic ASA is a Nordic pharma company with a footprint in Northern Europe.It is present in all Nordic countries, the Baltics and Benelux and has sales of specific products in other European countries like UK and Greece. The company’s headquarters are located in Oslo, Norway and it’s currently listed on the Oslo Stock Exchange (ticker: NAVA).
Their product portfolio, delivered to hospitals and through pharmacies, consists of prescription and OTC pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. Its business is divided into four segments: Specialty Pharma, Medical Nutrition, Branded Generics and Consumer Health. Within Specialty Pharma and Consumer Health, Navamedic focuses on specific categories like cardiology, obesity, gastro, women’s health, cough & cold and pain relief.
COOPER SA is one of the oldest pharmaceutical manufacturers in Greece. It was founded in 1936 and has had a continued presence in the pharmaceutical Greek pharmaceutical market up to the present day. Its aim is to establish itself as a dynamic pharmaceutical production unit, whilst developing partnerships with major companies abroad in the fields of both pharmaceutical medicine and medical devices.
Its modern manufacturing facilities in sterile ophthalmic solutions, small & large volume injectables and large volume parenteral solutions together with its quality control systems and procedures which ensure state of the art production and quality control standards, have all established COOPER’s position in the pharmaceutical market. With its distinguished history of past and present partnerships, COOPER SA has become an essential partner in the field of both production and distribution of sterile Pharmaceutical Products.
Dipharma S.A. is a Swiss specialty pharmaceutical company, developing high quality, improved, medicines for rare diseases. Dipharma S.A. is part of a third-generation group of family-owned companies that have grown to a global presence. With a portfolio of generic orphan products for the treatment of Phenylketonuria, Gaucher Disease, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma S.A. provides improved solutions for patients affected by inborn metabolic diseases at an affordable cost and with a global reach.
Dipharma SA works every day to provide high quality and highly pure products and develops improved therapeutical formulations, aiming at simplifying patients’ lives and increasing patient’s compliance and adherence to pharmacological treatments. Dipharma SA efforts are always focused on making these treatments accessible and sustainable to patients all over the world.
The Bio Arte, founded in 2020 on the initiative of Manuele Biazzo and Christian Duchow, is an innovative player in the field of biomolecular research, highly specialized on the microbiota.
Established and located in the heart of Malta, Europe — the Bio Arte is the first entrepreneurial company which is able to provide a molecular characterization service of the microbiota (skin, nasopharyngeal & intestinal) through an innovative patented and easy to interpret analysis method. The mission of Bio arte is to provide state of the art analysis of microbiota and its implications on the balance of our health.
The Bio Arte is constantly growing fueled by in-depth knowledge, cutting-edge technology and a team that is consistently up to date with the latest in scientific research distinguish the Maltese-based company. By virtue of The Bio Arte Institute for Sustainable Industrial Biotechnology, the company’s research findings achieve global dissemination.